MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Illumina Net Income 2011-2025 | ILMN
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Illumina
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.22 B | -1.16 B | 762 M | 656 M | - | 1 B | 826 M | 463 M | 462 M | - | 353 M | 125 M | 86.6 M | 125 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1 B | -1.22 B | 206 M |
Quarterly Net Income Illumina
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 150 M | 235 M | 705 M | -1.99 B | -126 M | -234 M | 3 M | -139 M | -3.82 B | -535 M | 86 M | 257 M | 317 M | 185 M | 147 M | - | 179 M | 179 M | 179 M | 239 M | 234 M | 296 M | 233 M | 210 M | 199 M | 209 M | 208 M | 68 M | 163 M | 128 M | 367 M | 104 M | 129 M | 120 M | 90 M | - | 118 M | 102 M | 137 M | 153 M | 93.5 M | 46.6 M | 60 M | 80.7 M | 31.4 M | 35.9 M | -22.6 M | 71.9 M | 29.7 M | 23.4 M | 26.2 M | 38.4 M | 20.2 M | 30.6 M | 24.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 705 M | -3.82 B | -2.23 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brainsway Ltd.
BWAY
|
-6.46 M | $ 17.13 | 1.66 % | $ 99.4 M |  Israel |
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
DarioHealth Corp.
DRIO
|
-59.4 M | $ 12.15 | 2.14 % | $ 345 M | Israel |
 |
DexCom
DXCM
|
542 M | $ 66.06 | -1.34 % | $ 25.5 B |  USA |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Exact Sciences Corporation
EXAS
|
-865 M | $ 101.57 | 0.07 % | $ 18.8 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.0 | 1.59 % | $ 172 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-112 M | $ 1.56 | -3.7 % | $ 1.98 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 38.95 | 0.82 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
3.9 B | $ 227.29 | 0.42 % | $ 166 B | USA |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 26.94 | -0.74 % | $ 815 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | China |
 |
Mettler-Toledo International
MTD
|
863 M | $ 1 408.65 | 1.08 % | $ 29.9 B |  Schweiz |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
NeoGenomics
NEO
|
-78.7 M | $ 12.15 | 2.53 % | $ 1.54 B | USA |
 |
Neogen Corporation
NEOG
|
-1.09 B | $ 6.84 | -0.36 % | $ 1.48 B | USA |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
-190 M | $ 19.9 | -3.21 % | $ 1.07 B | USA |
 |
Pacific Biosciences of California
PACB
|
-307 M | $ 2.12 | - | $ 538 M | USA |
 |
Celcuity
CELC
|
-112 M | $ 101.74 | -3.33 % | $ 4.01 B | USA |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
-12.6 M | $ 3.35 | -6.42 % | $ 107 K | USA |
 |
Koninklijke Philips N.V.
PHG
|
3.32 B | $ 26.46 | -0.62 % | $ 20 B |  Niderland |
 |
Co-Diagnostics
CODX
|
-35.3 M | $ 0.3 | -13.39 % | $ 8.8 M | USA |
 |
Precipio
PRPO
|
-5.85 M | $ 24.67 | -1.2 % | $ 32 M | USA |
 |
Quidel Corporation
QDEL
|
810 M | $ 28.82 | 0.07 % | $ 1.21 B | USA |
 |
IQVIA Holdings
IQV
|
1.37 B | $ 224.13 | 0.84 % | $ 40.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
83.6 M | $ 45.14 | -0.21 % | $ 10 B | Niderland |
 |
Guardant Health
GH
|
-436 M | $ 103.55 | 1.45 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
-27.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Sotera Health Company
SHC
|
44.4 M | $ 16.76 | -0.42 % | $ 4.74 B | USA |
 |
Soleno Therapeutics
SLNO
|
-176 M | $ 49.79 | -4.25 % | $ 2 B | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Thermo Fisher Scientific
TMO
|
6.34 B | $ 574.27 | 0.46 % | $ 219 B | USA |
 |
Charles River Laboratories International
CRL
|
22.2 M | $ 197.59 | 2.36 % | $ 10.2 B | USA |
 |
Trinity Biotech plc
TRIB
|
929 K | $ 0.96 | -10.6 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
-77.7 M | $ 31.39 | 1.47 % | $ 1.88 B | USA |
 |
Quotient Limited
QTNT
|
-111 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
871 M | $ 184.04 | 0.81 % | $ 20.4 B | USA |
|
Biodesix
BDSX
|
-42.9 M | $ 7.63 | -2.8 % | $ 989 M | USA |
 |
Myriad Genetics
MYGN
|
-127 M | $ 7.07 | -2.01 % | $ 641 M | USA |